Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment
Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment is a approved stage product being developed by Johnson & Johnson for MRSA. The current trial status is completed. This product is registered under clinical trial identifier NCT02029872. Target conditions include MRSA.
What happened to similar drugs?
1 of 2 similar drugs in MRSA were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029872 | Approved | Completed |
Competing Products
4 competing products in MRSA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 43 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 26 |
| Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder | Savara | Phase 3 | 34 |
| EDP-322 | Enanta Pharmaceuticals | Phase 1 | 19 |